UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/574,612	06/15/2006	Yousef Al-Abed	3268.1007-004	4212
21005 7590 10/20/2009 HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINIA ROAD			EXAMINER	
			DAVIS, ZINNA NORTHINGTON	
P.O. BOX 9133 CONCORD, MA 01742-9133			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			10/20/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/574,612	AL-ABED ET AL.			
Office Action Summary	Examiner	Art Unit			
	Zinna Northington Davis	1625			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 14 Ju This action is FINAL . 2b)☑ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-21 and 30-44 is/are pending in the a 4a) Of the above claim(s) 30-44 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-21 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examinet 10) ☐ The drawing(s) filed on is/are: a) ☐ access	r. from consideration.	Examiner.			
Applicant may not request that any objection to the orection Replacement drawing sheet(s) including the correction 11). The oath or declaration is objected to by the Ex.	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 04/05/06.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Art Unit: 1625

DETAILED ACTION

1. Claims 1-21 and 30-44 are pending. Claims 22-29 and 45-56 have been cancelled.

2. In the response filed July 14, 2009, Applicant have elected the invention of Group I, claims 1-21, without traverse. The election of a compound of formula (VIf) as a single species is also acknowledged. The compound is depicted below:

- 3. Based upon the response filed July 14, 2009, the election of species requirement is withdrawn; however, the restriction requirement is maintained.
- 4. Claims 30-44 are withdrawn from consideration. These claims have not been canceled.
- 5. Rejoinder of the method claims will be addressed upon allowance of claimed subject matter.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 10/574,612

Art Unit: 1625

8. Claim 13 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Page 3

Claim 13 should end in a period. Correction is appreciated.

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 10. Claim 21 is rejected under 35 U.S.C. 102(b) as being anticipate by Schwab et al. [U.S. Patent 5,814,627 (Reference A1, cited by Applicants)].

The instantly claimed invention is disclosed. At columns 47 and 48, see example 60. The compound is depicted as follows:

The claim is fully met when A_1 is =N-, A_2 is O, Ar is a monocyclic, six-member heteroaryl and D is substituted by dialkyl and hydroxyl.

- 11. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 1625

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

12. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ferles et al. [Reference U, citied by the Examiner] in view of Schwab et al (cited above).

The instantly claimed compounds are taught. At page 1229 of Ferles et al, see compounds IIIa, IIIb, IIIc, and IIId. The compounds are depicted as follows:

The difference between the instantly claimed compounds and the Ferles compounds is the saturation of the isoxazole compound.

Art Unit: 1625

Schwab et al teach a class of isoxazole compounds which are useful in the treatment of inflammation. At column 1, lines 43-50, see the compound of formula I. The isoxazole compound is depicted as follows:

The isoxazole compound can be represented by one double bond or two double bonds. The saturation of the isoxazole compound may vary.

It would have been obvious to one having ordinary skill in the art to replace the generic isoxazole compound of Schwab et al. in this class of anti-inflammatory compounds. There is motivation to modify one ring system for another when the pharmacological behavior of the compounds and the expectation of similar pharmaceutical properties are retained.

- 13. The Information Disclosure Statement filed April 5, 2006 has been considered.
- 14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682. The examiner can normally be reached on M-F.
- 15. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
- 16. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Art Unit: 1625

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Zinna Northington Davis/

Zinna Northington Davis Primary Examiner Art Unit 1625

Znd

10.16.2009